INCYTE CORP (INCY)
A+
Pipeline Grade
Financial Position (from SEC Filings)
$3,463.0M
Cash & Equivalents
$369.4M
Quarterly Burn Rate
$19,447M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (4 Assets)
| Drug | Phase | Indications |
|---|---|---|
|
RUXOLITINIB PHOSPHATE
JAKAFI XR |
APPROVED | Accelerated Phase Chronic Myelogenous Leukemia, Acute Lymphoblastic Leukemia, Acute Lymphoblastic Lymphoma, Acute Lymphocytic Leukemia, Acute Myelogenous Leukemia, Acute-graft-versus-host Disease, Advanced and/or Metastatic Solid Tumors, Advanced Malignancies, Advanced Solid Tumors, Advanced/Metastatic Unresectable Malignant Pleural Mesothelioma, Adverse Effects, Allogeneic Bone Marrow Transplantation, Alopecia Areata, Atopic Dermatitis, B-Cell Lymphoma, B-Cell Malignancies, Bladder Cancer, Blastic Phase Chronic Myelogenous Leukemia, BRAF V600E Mutation, BRCA1 Mutation, BRCA2 Mutation, Breast Cancer, Breast Carcinoma, Castration-Resistant Prostate Carcinoma, Chronic Graft Vs. Host Disease, Chronic Graft-versus-host Disease (cGVHD), Chronic Graft-versus-host-disease, Chronic Hand Dermatitis, Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia (CMML), Chronic Phase Chronic Myelogenous Leukemia, Chronic Phase Chronic Myeloid Leukemia, CML, CNS Lymphoma, Colorectal Cancer (CRC), Colorectal Cancer Metastatic |
|
RETIFANLIMAB-DLWR
ZYNYZ |
APPROVED | — |
|
PEMIGATINIB
PEMAZYRE |
APPROVED | — |
|
axatilimab-csfr
NIKTIMVO |
APPROVED | — |
Upcoming Catalysts
No upcoming catalysts detected for this company.
Active Clinical Trials (1)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT05429268 | Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory D... | PHASE3 | Active Not Recruiting | 82 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.